$IGC News

IGC Pharma Announces Addition Of Icahn School Of Medicine At Mount Sinai In New York As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation Associated With Alzheimer's Disease

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

IGC Pharma Adds Kerwin Medical Center In Dallas, Texas As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation In Alzheimer's Disease

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

IGC Pharma Receives Authorization In Colombia To Synthesize, Formulate, And Conduct Development Activities Involving Psilocybin At Its R&D Facility In Bogotá

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

IGC Pharma Enrolls ~80% Participants In Its Phase 2 CALMA Clinical Study Of IGC-AD1 For Agitation Associated With Alzheimer's Disease

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

IGC Pharma Activates New Clinical Trial Site At Tandem Clinical Research A Prolerity Network Site In Metairie, Louisiana, For Ongoing Phase 2 CALMA Clinical Trial Evaluating IGC-AD1 For Agitation In Alzheimer's Dementia

IGC Pharma Activates New Clinical Trial Site At Tandem Clinical Research A Prolerity Network Site In Metairie, Louisiana, For Ongoing Phase 2 CALMA Clinical Trial Evaluating IGC-AD1 For Agitation In Alzheimer's Dementia

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

IGC Pharma, New to The Street launch 12-part national media partnership

New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates